108 related articles for article (PubMed ID: 3754490)
21. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphocytic leukemia: Phase I Pilot Study for the Eastern Cooperative Oncology Group.
Hines JD; Mazza JJ; Oken MM; Bennett JM; Adelstein DJ; Keller A; O'Connell MJ
Semin Oncol; 1985 Jun; 12(2 Suppl 3):117-9. PubMed ID: 3839318
[No Abstract] [Full Text] [Related]
22. Amsacrine in refractory acute leukemia.
Griffin JD; Maguire ME; Mayer RJ
Cancer Treat Rep; 1985; 69(7-8):787-9. PubMed ID: 3860296
[TBL] [Abstract][Full Text] [Related]
23. [Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
Cabanillas F
Sangre (Barc); 1981; 26(5B):885-9. PubMed ID: 6172860
[No Abstract] [Full Text] [Related]
24. Phase II study of amsacrine gluconate in refractory leukemia.
Omura GA; Winton EF; Vogler WR; Zuckerman KS; Grillo-Lopez AJ
Cancer Treat Rep; 1983 Dec; 67(12):1131-2. PubMed ID: 6580948
[TBL] [Abstract][Full Text] [Related]
25. Acute electrocardiographic changes induced by amsacrine.
Shinar E; Hasin Y
Cancer Treat Rep; 1984 Sep; 68(9):1169-72. PubMed ID: 6592038
[TBL] [Abstract][Full Text] [Related]
26. Phase II Study of AMSA, prednisone, and chlorambucil (APC) in the treatment of refractory breast cancer: a Northern California Oncology Group Study.
Friedman MA; Marcus F; Kohler M; Resser KJ
Cancer Treat Rep; 1982 May; 66(5):1235-6. PubMed ID: 7083225
[No Abstract] [Full Text] [Related]
27. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer.
Tannir N; Spitzer G; Schell F; Legha S; Zander A; Blumenschein G
Cancer Treat Rep; 1983 Jun; 67(6):599-600. PubMed ID: 6344995
[No Abstract] [Full Text] [Related]
28. [A new drug and current strategy in the treatment of acute non-lymphocytic leukemia in adults].
Ogawa M
Gan To Kagaku Ryoho; 1986 May; 13(5):1829-36. PubMed ID: 3754711
[TBL] [Abstract][Full Text] [Related]
29. Amsacrine combined with etoposide and high-dose methylprednisolone as salvage therapy in acute lymphoblastic leukemia in children.
Horstmann MA; Hassenpflug WA; zur Stadt U; Escherich G; Janka G; Kabisch H
Haematologica; 2005 Dec; 90(12):1701-3. PubMed ID: 16330449
[TBL] [Abstract][Full Text] [Related]
30. Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.
Kröger N; Zabelina T; Sonnenberg S; Krüger W; Renges H; Stute N; Finkenstein F; Mayer U; Holstein K; Fiedler W; Colberg H; Sonnen R; Kuse R; Braumann D; Metzner B; del Valle F; Erttmann R; Kabisch H; Zander AR
Bone Marrow Transplant; 2000 Oct; 26(7):711-6. PubMed ID: 11042650
[TBL] [Abstract][Full Text] [Related]
31. Cyclophosphamide/etoposide: effective reinduction therapy for children with acute nonlymphocytic leukemia in relapse.
Kalwinsky DK; Dahl GV; Mirro J; Look AT
Cancer Treat Rep; 1985; 69(7-8):887-9. PubMed ID: 4016796
[TBL] [Abstract][Full Text] [Related]
32. Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
Winton EF; Hearn EB; Vogler WR; Johnson L; Logan T; Raney M
Cancer Treat Rep; 1983 Nov; 67(11):977-80. PubMed ID: 6580070
[TBL] [Abstract][Full Text] [Related]
33. Combination chemotherapy with diaziquone and amsacrine in relapsed and refractory acute nonlymphocytic leukemia: a Cancer and Leukemia Group B Study.
Schiffer CA; Davis RB; Mayer RJ; Peterson BA; Lee EJ
Cancer Treat Rep; 1987 Sep; 71(9):879-80. PubMed ID: 3621225
[No Abstract] [Full Text] [Related]
34. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[TBL] [Abstract][Full Text] [Related]
35. Induction chemotherapy for acute myelogenous leukemia.
Kalaycio M
Curr Hematol Rep; 2005 Jan; 4(1):49-50. PubMed ID: 15610659
[No Abstract] [Full Text] [Related]
36. Treatment of relapsed or refractory acute leukemia: comparison of two different regimens.
Marit G; Cony P; Duclos F; Puntous M; Broustet A; Reiffers J
Haematol Blood Transfus; 1990; 33():614-8. PubMed ID: 2323662
[No Abstract] [Full Text] [Related]
37. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
38. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
[TBL] [Abstract][Full Text] [Related]
39. [Phase II study of etoposide (NK 171) in advanced hematological malignancies].
Yoshida T; Nakanishi J; Ito K; Kobayashi S; Ohtake S; Nakamura S; Hattori K
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1579-84. PubMed ID: 6476835
[TBL] [Abstract][Full Text] [Related]
40. Phase II trial of cisplatin and etoposide in adenocarcinomas of the upper gastrointestinal tract.
Kelsen DP; Buckner J; Einzig A; Magill G; Heelan R; Vinciguerra V
Cancer Treat Rep; 1987 Mar; 71(3):329-30. PubMed ID: 3815400
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
